Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


22.11.2021

1 Acta Haematol
1 Am J Hematol
1 Biochem Pharmacol
8 Blood
2 Bone Marrow Transplant
1 Cancer
1 Cancer Chemother Pharmacol
1 Eur J Haematol
1 Eur J Immunol
1 Int J Hematol
1 J Clin Oncol
2 Leuk Lymphoma
2 Leuk Res
5 Leukemia
1 N Engl J Med
2 Oncol Rep
1 PLoS Biol
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Haematol

  1. SHAHIN OA, Chifotides HT, Bose P, Masarova L, et al
    Accelerated Phase of Myeloproliferative Neoplasms.
    Acta Haematol. 2021;144:484-499.
    PubMed         Abstract available


    Am J Hematol

  2. CHO BS, Min GJ, Park SS, Yoon SY, et al
    Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.
    Am J Hematol. 2021;96:1441-1449.
    PubMed         Abstract available


    Biochem Pharmacol

  3. VIGON L, Martinez-Roman P, Rodriguez-Mora S, Torres M, et al
    Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy.
    Biochem Pharmacol. 2021;192:114666.
    PubMed         Abstract available


    Blood

  4. ANDRIEU GP, Asnafi V
    Integrated omics approaches to predict T-LBL relapse risk.
    Blood. 2021;137:2280-2282.
    PubMed        

  5. PADI SKR, Kraft AS
    "Root"ing for successful T-ALL treatment.
    Blood. 2021;137:2422-2423.
    PubMed        

  6. GANSER A
    What can Heraclitus tell us about AML?
    Blood. 2021;137:2719-2720.
    PubMed        

  7. FOWLER N
    Kinase inhibitors in CLL: drawing the roadmap.
    Blood. 2021;137:2717-2719.
    PubMed        

  8. GHIA P, Stamatopoulos K
    In CLL, epigenetics also points to the BCR.
    Blood. 2021;137:2863-2865.
    PubMed        

  9. ZHAO H, Pomicter AD, Eiring AM, Franzini A, et al
    MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common beta Chain Cytokine Receptor Endocytosis.
    Blood. 2021 Nov 15. pii: 477970. doi: 10.1182/blood.2021011802.
    PubMed         Abstract available

  10. GOSWAMI S, Mani R, Nunes J, Chiang CL, et al
    PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia.
    Blood. 2021 Nov 17. pii: 482661. doi: 10.1182/blood.2020010344.
    PubMed         Abstract available

  11. ZHONG W, Cao X, Pan G, Niu Q, et al
    ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1.
    Blood. 2021 Nov 19. pii: 482705. doi: 10.1182/blood.2021013579.
    PubMed         Abstract available


    Bone Marrow Transplant

  12. SCHETELIG J, Hoek J, Stilgenbauer S, Middeke JM, et al
    Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study.
    Bone Marrow Transplant. 2021 Nov 12. pii: 10.1038/s41409-021-01524.
    PubMed        

  13. SCHETELIG J, Chevallier P, van Gelder M, Hoek J, et al
    Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
    Bone Marrow Transplant. 2021 Nov 12. pii: 10.1038/s41409-021-01516.
    PubMed        


    Cancer

  14. PRINTZ C
    First Person Profile: Cheryl Willman, MD: As director and CEO of the University of New Mexico Comprehensive Cancer Center, Dr. Willman has led major health equity initiatives while making pioneering discoveries in precision medicine.
    Cancer. 2021;127:1357-1358.
    PubMed        


    Cancer Chemother Pharmacol

  15. PANETTA JC, Liu Y, Bottiglieri T, Arning E, et al
    Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
    Cancer Chemother Pharmacol. 2021;88:655-664.
    PubMed         Abstract available


    Eur J Haematol

  16. CUNNINGHAM I, Sosa SS, Hamele-Bena D
    A single organ microenvironment and the common features of tumors of leukemia, lymphoma, and myeloma cells growing there. A literature review.
    Eur J Haematol. 2021 Nov 15. doi: 10.1111/ejh.13727.
    PubMed         Abstract available


    Eur J Immunol

  17. GLOBERSON LEVIN A, Riviere I, Eshhar Z, Sadelain M, et al
    CAR T cells: Building on the CD19 paradigm.
    Eur J Immunol. 2021;51:2151-2163.
    PubMed         Abstract available


    Int J Hematol

  18. NAKAMAE M, Nakamae H, Hashimoto M, Koh H, et al
    Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors.
    Int J Hematol. 2021 Nov 17. pii: 10.1007/s12185-021-03259.
    PubMed         Abstract available


    J Clin Oncol

  19. SHAW BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, et al
    National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.
    J Clin Oncol. 2021 Apr 27:JCO2003502. doi: 10.1200/JCO.20.03502.
    PubMed         Abstract available


    Leuk Lymphoma

  20. KHANAL N, Shostrom V, Dhakal P, Upadhyay Banskota S, et al
    Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis.
    Leuk Lymphoma. 2021 Nov 17:1-7. doi: 10.1080/10428194.2021.2005046.
    PubMed         Abstract available

  21. YUE X, Hincapie AL, Li Y, Guo JJ, et al
    Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.
    Leuk Lymphoma. 2021 Nov 15:1-9. doi: 10.1080/10428194.2021.2002320.
    PubMed         Abstract available


    Leuk Res

  22. LUGER SM, Wang VX, Rowe JM, Litzow MR, et al
    Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
    Leuk Res. 2021;111:106736.
    PubMed         Abstract available

  23. GALASSI L, Colasante C, Bettelli F, Gilioli A, et al
    Pre-existing cytopenia heralding de novo acute myeloid leukemia: Uncommon presentation of NPM1-mutated AML in a single-center study.
    Leuk Res. 2021;111:106747.
    PubMed        


    Leukemia

  24. GOURVEST M, De Clara E, Wu HC, Touriol C, et al
    A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA.
    Leukemia. 2021;35:2784-2798.
    PubMed         Abstract available

  25. STETSON LC, Balasubramanian D, Ribeiro SP, Stefan T, et al
    Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression.
    Leukemia. 2021;35:2799-2812.
    PubMed         Abstract available

  26. WALTER RB, Hochhaus A, Gale RP
    Elihu H. Estey, MD: leukemia expert, statistician, and gentle soul (July 15, 1946-October 8, 2021).
    Leukemia. 2021 Nov 16. pii: 10.1038/s41375-021-01467.
    PubMed        

  27. ROESSNER PM, Seiffert M
    Publisher Correction: T cells in chronic lymphocytic leukemia: guardians or drivers of disease?
    Leukemia. 2021 Nov 16. pii: 10.1038/s41375-021-01362.
    PubMed        

  28. HORAK P, Uhrig S, Witzel M, Gil-Farina I, et al
    Publisher Correction: Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia.
    Leukemia. 2021 Nov 16. pii: 10.1038/s41375-021-01364.
    PubMed        


    N Engl J Med

  29. WOO SB, Wu MY, Treister NS, Amrein PC, et al
    Case 33-2021: A 68-Year-Old Man with Painful Mouth Ulcers.
    N Engl J Med. 2021;385:1700-1710.
    PubMed        


    Oncol Rep

  30. LIANG X, Xia R
    Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia.
    Oncol Rep. 2022;47.
    PubMed         Abstract available

  31. ZHANG P, Wang Y, Qin M, Li D, et al
    Involvement of Blnk and Foxo1 in tumor suppression in BCRABL1transformed proB cells.
    Oncol Rep. 2021;45:693-705.
    PubMed         Abstract available


    PLoS Biol

  32. WANG J, Farkas C, Benyoucef A, Carmichael C, et al
    Interplay between the EMT transcription factors ZEB1 and ZEB2 regulates hematopoietic stem and progenitor cell differentiation and hematopoietic lineage fidelity.
    PLoS Biol. 2021;19:e3001394.
    PubMed         Abstract available


    PLoS One

  33. HOFFMANN H, Baldow C, Zerjatke T, Gottschalk A, et al
    How to predict relapse in leukemia using time series data: A comparative in silico study.
    PLoS One. 2021;16:e0256585.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: